Waldner M, Neurath M (2014)
Publication Type: Journal article
Publication year: 2014
Book Volume: 26
Pages Range: 75-9
Journal Issue: 1
DOI: 10.1016/j.smim.2013.12.003
IL-6 signaling is of central importance for the maintenance of chronic intestinal inflammation in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. IL-6 regulates T cell differentiation, activation and resistance against apoptosis and thereby controls the balance between pro-inflammatory T cell subsets such as Th1 or Th17 cells and immunosuppressive regulatory T cells. Furthermore, IL-6 has been implicated in the pathogenesis of colorectal cancer (CRC). In fact, IL-6 directly promotes tumor cell proliferation and survival through STAT3 activation. Due to its role in both types of diseases, IL-6 has been proposed as a missing link between inflammation and tumor development. During recent years, several therapeutics targeting IL-6 dependent pathways have been developed. Although clinical data about anti-IL-6 treatment in intestinal diseases are currently scarce, targeting this pathway might be a promising strategy in IBD and CRC.
APA:
Waldner, M., & Neurath, M. (2014). Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Seminars in Immunology, 26(1), 75-9. https://dx.doi.org/10.1016/j.smim.2013.12.003
MLA:
Waldner, Maximilian, and Markus Neurath. "Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development." Seminars in Immunology 26.1 (2014): 75-9.
BibTeX: Download